Mecasermin rinfabate

Mecasermin rinfabate Brand Name– Iplex

What is Mecasermin rinfabate

NOTE: This drug is discontinued in the U.S.

Mecasermin rinfabate rh-IGF-1/rh-IGFPB-3 (IPLEX) was a recombinant human complex consisting of insulin-like growth factor-1 (rh-IGF-1) and insulin-like growth factor binding protein-3 (rh-IGFBP-3) bound in a 1:1 ratio.

IGF-1 is the primary mediator of growth hormone (GH) and has many actions in the body including the promotion of skeletal, organ, and other tissue growth, the suppression of hepatic glucose production, the inhibition of insulin secretion, and the maintenance and regeneration of the nervous system.

Mecasermin rinfabate was FDA approved in 2005 for the treatment of growth failure in children with severe primary IGF deficiency or with GH gene deletion who have developed neutralizing antibodies to GH; however, the product was discontinued from marketing in 2009.

Indications

  1. growth failure
  2. growth hormone (GH) gene deletion
  3. primary insulin-like growth factor (IGF-1) deficiency

For the long-term treatment of growth failure in children with severe primary insulin-like growth factor (IGF-1) deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH

Side Effects

  1. anaphylactoid reactions
  2. anemia
  3. antibody formation
  4. arthralgia
  5. bone pain
  6. cardiac valvulopathy
  7. edema
  8. elevated hepatic enzymes
  9. erythema
  10. headache
  11. hematuria
  12. hepatomegaly
  13. hyperglycemia
  14. hypoglycemia
  15. increased intracranial pressure
  16. injection site reaction
  17. lymphadenopathy
  18. papilledema
  19. splenomegaly

Monitoring Parameters

  • blood glucose
  • growth rate
  • ophthalmologic exam
  • serum cholesterol
  • serum IGF-1 concentrations
  • serum triglycerides

Contraindications

  • breast-feeding
  • children
  • corticosteroid therapy
  • diabetes mellitus
  • driving or operating machinery
  • epiphyseal closure
  • hypoglycemia
  • hypothyroidism
  • increased intracranial pressure
  • infants
  • intravenous administration
  • malnutrition
  • neonates
  • neoplastic disease
  • pregnancy
  • scoliosis
  • sleep apnea

Interactions

  • Acarbose
  • Acetohexamide
  • Albiglutide
  • Alogliptin
  • Alogliptin; Metformin
  • Alogliptin; Pioglitazone
  • Antidiabetic Agents
  • Canagliflozin
  • Canagliflozin; Metformin
  • Chlorpropamide
  • Corticosteroids
  • Dapagliflozin
  • Dapagliflozin; Metformin
  • Dapagliflozin; Saxagliptin
  • Dulaglutide
  • Empagliflozin
  • Empagliflozin; Linagliptin
  • Empagliflozin; Linagliptin; Metformin
  • Empagliflozin; Metformin
  • Ertugliflozin
  • Ertugliflozin; Metformin
  • Ertugliflozin; Sitagliptin
  • Exenatide
  • Glimepiride
  • Glimepiride; Pioglitazone
  • Glimepiride; Rosiglitazone
  • Glipizide
  • Glipizide; Metformin
  • Glyburide
  • Glyburide; Metformin
  • Insulin Aspart
  • Insulin Aspart; Insulin Aspart Protamine
  • Insulin Degludec; Liraglutide
  • Insulin Detemir
  • Insulin Glargine
  • Insulin Glargine; Lixisenatide
  • Insulin Glulisine
  • Insulin Lispro
  • Insulin Lispro; Insulin Lispro Protamine
  • Insulin, Inhaled
  • Isophane Insulin (NPH)
  • Lente Insulin
  • Linagliptin
  • Linagliptin; Metformin
  • Liraglutide
  • Lixisenatide
  • Metformin
  • Metformin; Pioglitazone
  • Metformin; Repaglinide
  • Metformin; Rosiglitazone
  • Metformin; Saxagliptin
  • Metformin; Sitagliptin
  • Miglitol
  • Nateglinide
  • Octreotide
  • Pegvisomant
  • Pioglitazone
  • Pramlintide
  • Regular Insulin
  • Regular Insulin; Isophane Insulin (NPH)
  • Repaglinide
  • Rosiglitazone
  • Saxagliptin
  • Semaglutide
  • Simvastatin; Sitagliptin
  • Sitagliptin
  • Somatropin, rh-GH
  • Tolazamide
  • Tolbutamide
  • Ultralente Insulin
  • Vigabatrin
You cannot copy content of this page